drugset / Trial / NCT03740243

Buprenorphine vs Buprenorphine/Naloxone on the Effects of Maternal Symptomatology

NCT03740243

Phase 4 Withdrawn Stony Brook University
RandomizedParallel-groupOpen-labelTreatment

Summary

This study will assesses the efficacy of buprenorphine/naloxone vs buprenorphine on maternal withdrawal symptoms and drug cravings. This is a randomized controlled trial to a cohort of pregnant women seeking medication-assisted treatment for opioid use disorders. Half of participants will receive buprenorphine, while the other half of participants receive a combination of buprenorphine/naloxone

Timeline

Start
2018-11-30
Primary completion
2020-03-22
Completion
2020-03-22

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Buprenorphine Other / unclassified 2 mg
Comparator Buprenorphine Other / unclassified 4 mg
Comparator Buprenorphine Other / unclassified 8 mg
Comparator Buprenorphine Other / unclassified 16 mg
Subject Naloxone Small molecule 1 mg
Subject Naloxone Small molecule 2 mg